Cerebrolysin identity is confirmed by profile, not by one mass. It is a pig-brain peptide mix with hundreds of peptides and free amino acids. Labs compare its HPLC fingerprint, and sometimes an LC-MS profile, with a reference. A match says the pattern agrees. It does not name every part.
- Cerebrolysin has no single formula or mass, so identity is a profile comparison.
- Reversed-phase HPLC fingerprints separated Cerebrolysin from other brain-derived preparations in a 2024 study.
- An LC-MS study identified 638 unique peptides in one sample, mainly from tubulin, actin and myelin basic protein.
- A fingerprint match is only as good as the stated method and the named reference.
- A single observed molecular weight reported as identity is a red flag for this material.
What does identity mean for a mixture?
For a mixture, identity means the whole pattern matches a reference, not that one molecule is present. How do you prove a bowl of soup is the soup on the menu? You cannot point to one ingredient. You taste it, look at it, and compare it with what that soup is supposed to be like. Identity for Cerebrolysin is closer to that than to checking a single molecule.
For a defined peptide such as Semax, identity is a clean question. The formula gives one theoretical mass, a mass spectrometer measures one observed mass, and the two either agree or they do not. Cerebrolysin has no formula. The Cochrane review describes it as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain, and a laboratory paper from 2001 describes a standardized enzymatic breakdown of porcine brain proteins giving roughly 75 percent free amino acids and 25 percent peptides.
So the plain answer is this: there is no single mass to confirm. Identity for this material is a fingerprint comparison. A sample is run through a method that spreads its components into a pattern, and that pattern is compared with a reference pattern produced the same way.
- Label and name: a claim only
- Single purity figure: undefined for a mixture
- HPLC fingerprint against a named reference
- LC-MS profile against a reference
- Two independent methods agreeing
The HPLC fingerprint
Reversed-phase HPLC separates peptides by how strongly they stick to a hydrophobic column as the solvent grows richer in organic. A single peptide gives one main peak. A digest of brain protein gives a crowded trace of many peaks, some sharp, some overlapping, spread across the run.
That trace is the fingerprint. It depends on the column, the mobile phases, the gradient, the temperature and the detection wavelength, so a comparison is meaningful only when the sample and the reference were run under the same stated conditions, ideally in the same sequence on the same day.
The approach has been used in published work to tell preparations apart. Seidl and Aigner, writing in 2024, compared several brain-derived peptide products sold as similar to Cerebrolysin and obtained each one's peptide fingerprint by reversed-phase HPLC. The chromatograms differed clearly from Cerebrolysin's, and products from different makers using brain protein hydrolysate were not comparable with each other either. That is exactly the kind of difference a fingerprint is built to catch.
LC-MS peptide profiling
Mass spectrometry adds a second, much more detailed layer. Coupled to liquid chromatography, it records the masses of the ions eluting at each point in the run, and with fragmentation it can assign sequences to many individual peptides.
The published numbers show how deep this goes. Gevaert and colleagues profiled one Cerebrolysin sample bought online, using HPLC with electrospray ion-trap detection and ultra-high-performance LC with ion mobility and time-of-flight detection. They identified 638 unique peptides, most of them fragments of tubulin, actin and myelin basic protein. They did not detect fragments of several well-known neurotrophic factors they looked for. A 2019 Orbitrap study of one lighter fraction assigned sequences to 14,635 peptides mapping to 1,643 porcine proteins.
Those are research studies, not routine lot tests. For a certificate, the practical use of LC-MS is narrower: showing that the main ions and their pattern agree with a reference. It can also flag something clearly wrong, such as a sample dominated by a single synthetic peptide, which a real tissue digest would never be. The LC-MS identity guide explains the method for defined peptides.
What does a fingerprint match prove?
A fingerprint match shows the overall pattern agrees with the reference; it does not identify every component.
| Evidence | What it shows | Limit |
|---|---|---|
| Label and name | What the seller claims | Unverified |
| Single purity percentage | Nothing clear for a mixture | No single main peak to measure against |
| HPLC fingerprint against a reference | The overall pattern agrees | Only as good as the reference and the method |
| LC-MS profile against a reference | Many component masses agree | Still a comparison, not a full census |
| Composition results | Peptide and amino acid content in range | Says how much, not which |
A fingerprint match says the sample looks like the reference by that method. It does not sequence every component, and it cannot rule out small changes hidden inside overlapping peaks. Two different digests could, in principle, give similar-looking traces on one gradient. That is why a strong report stacks methods: two independent techniques agreeing is far better evidence than one.
The reference is the weak point to watch. A match to a well-documented retained lot means something. A match to an unnamed "standard" means much less.
Why the reference matters so much
Every fingerprint comparison has two halves, and the reference half gets less attention than it deserves. For a synthetic peptide, a reference standard can be made to a known structure and checked independently. For a tissue digest there is no structure to check against. The reference is itself a lot of the same kind of material, and its authority comes from how well it was documented.
A strong reference is a retained sample from a lot with full documentation, stored under recorded conditions, and run alongside the test sample on the same method. A weak one is a chromatogram from an old report, run on different equipment, or a trace described only as "typical".
The 2024 comparison work shows why this matters. Preparations described as similar to Cerebrolysin gave clearly different fingerprints, and products from different makers differed from each other. If a laboratory compared a sample only against a trace from one of those other products, it could report a match that meant nothing about Cerebrolysin at all.
A certificate should therefore name the reference, say where it came from, and say when it was run. Without that, a "conforms" line has no fixed point.
Why can one mass not confirm Cerebrolysin?
One mass cannot confirm Cerebrolysin because a mixture has no single molecular weight. Some certificates for this product copy the layout used for synthetic peptides: one theoretical molecular weight, one observed molecular weight, and "conforms". For Cerebrolysin, that layout has nothing true to say. There is no theoretical molecular weight for a mixture of hundreds of peptides and free amino acids. If a document reports one, either the laboratory measured a single dominant ion and called it identity, or the numbers came from a template.
The first case is a problem in its own right. A real porcine brain digest should not collapse to one dominant peptide. A sample that does is not the material its name describes, whatever it is.
The same caution applies to purity. On a defined peptide, the difference between purity and identity is already important. On a mixture, a purity percentage has no agreed meaning at all unless the document defines it.
Composition as a supporting check
Identity by fingerprint works best with composition results beside it. A peptide or amino acid content figure says whether the amounts sit where they should. The 2001 description of about 75 percent free amino acids and 25 percent peptides shows the kind of balance involved, though a lot's own figures come from its own testing.
Amino acid analysis, where the sample is fully hydrolyzed and the resulting amino acids are measured, is one way to get there. It cannot tell peptides apart, because it breaks them all down, but it does show whether the overall amino acid makeup is plausible for a brain protein digest. A sample that came back as nearly pure glycine, for example, would fail that check no matter what its chromatogram looked like.
No single test settles identity for a mixture. The evidence gets stronger as independent results agree.
Checking the report for your vial
For our SKU CBL60, a 60 mg lyophilized vial listed on the Cerebrolysin product page, identity documentation belongs to the lot. Check that the lot number on the report matches the vial. Look for the chromatogram, the stated method and the named reference. Then confirm the report number with the issuing laboratory.
The FDA's copy of ICH Q6B frames identity, purity and quantity as separate items with separate procedures. A mixture keeps that separation: the fingerprint speaks to identity, composition results speak to quantity, and neither substitutes for the other.
Our certificates are published lot by lot on the certificate page. A product page shows results only once the certificate for that lot is published. The Cerebrolysin certificate guide goes row by row, and the storage guide covers why a mixture kept badly can drift from its reference pattern.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
What is Cerebrolysin studied for?
Published research on Cerebrolysin investigates the areas below, which is a different question from what Cerebrolysin will do for anyone, a claim about a living system that nothing on this site is sold for.
What it is. A peptide preparation produced by enzymatic breakdown of purified porcine brain protein — a mixture of low-molecular-weight peptides and free amino acids, not a defined molecule.
What the research looks at. Acute ischaemic stroke, vascular dementia and traumatic brain injury, principally in trials conducted in Europe and Asia. Registered and used in a number of countries; not approved in the United States.
How it is thought to work. Not established. Proposed to act as a neurotrophic mixture, but the preparation has no single active constituent, no defined receptor and no characterized pharmacokinetics in the sense a single compound would have.
What is not established. Efficacy. The pooled randomised evidence in acute ischaemic stroke does not demonstrate benefit on functional outcome. For a mixture rather than a molecule, identity and purity testing also cannot mean what they mean for a defined compound.
The full record, including the certificate for the lot in stock, is on the Cerebrolysin product page.
Common questions
Can mass spectrometry confirm Cerebrolysin with one number?
What is a peptide fingerprint?
How many peptides are in Cerebrolysin?
What should make me doubt a Cerebrolysin identity result?
More documentation guides
Sources
- Cochrane Database of Systematic Reviews, Cerebrolysin for acute ischaemic stroke (2023). Used only for its description of the preparation as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain.
- Journal of Neural Transmission (2001), Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons. Used only for its description: a standardized enzymatic breakdown of porcine brain proteins, about 75% free amino acids and 25% low-molecular-weight peptides.
- Seidl and Aigner, Journal of Medicine and Life (2024), comparing the composition of Cerebrolysin with other peptide preparations. Peptide fingerprints by reversed-phase HPLC separated Cerebrolysin from other brain-derived preparations, which also differed from each other.
- Gevaert and colleagues, Drug Testing and Analysis (2015), peptide profiling of Internet-obtained Cerebrolysin by LC-MS. 638 unique peptides identified in one sample, mainly fragments of tubulin, actin and myelin basic protein.
- Gromova and colleagues, Zhurnal Nevrologii i Psikhiatrii (2019), peptide composition of a light fraction of Cerebrolysin. Orbitrap mass spectrometry assigned sequences to 14,635 peptides mapping to 1,643 porcine proteins in one fraction.
- FDA, Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (1999). The ICH framework that treats identity, purity and quantity as separate specification items.
